Polymyalgia rheumatica (PMR) is the second most common autoimmune rheumatic disorder; giant cell ... criteria are still used, but are less helpful for classifying GCA without temporal arteritis.

Discover why headaches strike one side of your head, from migraines to nerve disorders, and learn the warning signs that ...

Exclusion criteria included presence of a severe ... 70% had polymyalgia rheumatica, 14% giant cell arteritis, and 16% both. Median duration on prednisolone was 13 months (mean cumulative dose ...

The following is a summary of “Population-Based Performance of Inflammatory Markers in Giant Cell Arteritis,” published in the March ... GCA followed the 1990 American College of Rheumatology criteria ...

Germany Background Giant cell arteritis (GCA) is an immune-mediated, granulomatous vasculitis that primarily affects the elderly and results in local vascular changes of middle-sized and large ...

Background: The treatment of giant cell arteritis (GCA) relies on corticosteroids but is ... Patients had to satisfy the following two criteria to be enrolled in this retrospective study. First, their ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

The following is a summary of “Biomarkers of ocular manifestation in newly diagnosed giant cell arteritis,” published in the April 2025 issue of BMC Ophthalmology by Terheyden et al. Giant cell ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...